WebSite > Guangzhou Viocon Pharmaceutical Technology Co., Ltd

Guangzhou Viocon Pharmaceutical Technology Co., Ltd

  • Company Name Guangzhou Viocon Pharmaceutical Technology Co., Ltd
  • Tel -
  • Email pengguizi@cti-cert.com
  • WebSite 
  • CB Index 58
  •       Guangzhou CTI-Viokind Pharmaceutical Technology Co., Ltd., established in 2016, is a wholly-owned subsidiary under the listed group CTI Testing Group [Stock Code: 300012]. It is recognized as a National High-Tech Enterprise, Guangdong Provincial Specialized and Sophisticated SME, and Guangzhou Exemplary Science and Technology Service Institution. As part of CTI Testing Group's Pharmaceutical and Medical Division, CTI-Viokind specializes in providing professional pharmaceutical CMC (Chemistry, Manufacturing, and Controls) research, testing services, and consulting solutions to domestic pharmaceutical companies and research institutions. Upholding rigorous scientific ethics, the company delivers on its commitments to clients and has earned widespread acclaim for its exceptional technical services and business development capabilities in the industry. CTI-Viokind offers end-to-end service capabilities spanning drug synthesis, formulation and process development, quality studies, stability testing, and drug registration. Its core services include: CMC Research for Chemical APIs，CMC Research for Small-Molecule Formulations，Quality-Related Project Studies，CMC Research for Traditional Chinese Medicine Formulations，MAH (Marketing Authorization Holder) and Registration Consulting Services.
Guangzhou Viocon Pharmaceutical Technology Co., Ltd Product List
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  • Product Name Retinol
  • MF C20H30O
  • CAS 69686-69-7
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •